Welcome to our dedicated page for Qilian International Holding Group Ltd. Ordinary Shares news (Ticker: QLI), a resource for investors and traders seeking the latest updates and insights on Qilian International Holding Group Ltd. Ordinary Shares stock.
This news page for Qilian International Holding Group Ltd (historically Nasdaq: QLI) provides an archive of company announcements, regulatory updates and corporate actions that were released while the shares traded under the QLI ticker. The company has described itself as a China-based pharmaceutical and chemical products manufacturer, headquartered in Gansu, China, with a focus on licorice products, oxytetracycline products, traditional Chinese medicine derivatives products, heparin products, sausage casings, and fertilizers.
News items in this archive include communications about Nasdaq listing compliance, such as notifications of minimum bid price deficiencies, extensions to regain compliance, and the company’s subsequent confirmation that it had met the minimum bid price requirement. Readers will also find detailed announcements about the 1-for-5 reverse share split approved by the board of directors, including how the split affected Class A and Class B ordinary shares and the handling of fractional shares.
Other press releases cover strategic and industrial adjustments, where Qilian International outlined plans to reduce investment in oxytetracycline due to market and regulatory pressures, increase investment in heparin sodium, develop licorice-based products such as licorice extract, fluid extract and compound licorice lozenges, and allocate capital to financial products and software development. The archive also includes dividend declarations and interim financial result summaries that discuss revenue trends and segment performance across heparin products, oxytetracycline products, licorice products, traditional Chinese medicine derivatives, sausage casings and fertilizers.
In August 2024, the company announced that its Class A ordinary shares would begin trading under the ticker symbol BGM, replacing QLI, while remaining listed on the Nasdaq Capital Market. For users tracking the evolution of the business from QLI to BGM, this page offers historical context on how the company communicated with investors during that period.
Qilian International Holding Group Limited (Nasdaq: QLI) announced an investment agreement with Chongqing Jin Tong Industrial Construction Investment Co. Ltd. for a pig by-product processing facility in Chongqing. The project, covering 50 mu (8.24 acres), will require an investment of RMB540 million (USD83.6 million) and is expected to produce 10 tons of heparin sodium preparations annually within three years, valued at over RMB500 million (USD77.4 million). The project aligns with QLI's strategy to expand its heparin production capacity.
Qilian International Holding Group Limited (Nasdaq: QLI) has signed an exclusive agency agreement with Henan Kangzhiyuan Pharmaceutical Co., Ltd. to enhance sales of its Gan Di Xin® product, a licorice-based medication. The agreement, effective from April 22, 2021, spans five years and aims to leverage mutual resources for better market penetration. Gan Di Xin® is known for its innovative formulation and effectiveness as an antitussive and expectorant. The collaboration is expected to significantly boost sales through Kangzhiyuan's extensive national marketing channels.
Qilian International Holding Group Limited (Nasdaq: QLI) announced that 16 of its pharmaceutical products have been added to China's National Reimbursement Drugs List. This list significantly enhances patient access to these medications, including those for coronary heart disease and urinary tract infections. Additionally, 10 of these products are now part of the National Essential Medicines List, further solidifying their market position. The inclusion is expected to boost demand as patients will receive reimbursements for these listed drugs.
Jiuquan, China, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Qilian International Holding Group Limited (Nasdaq: QLI) announced that Chairman and CEO, Mr. Zhanchang Xin, received the Outstanding Entrepreneur Award from the Economic and Technological Development Zone of Jiuquan City. This recognition highlights the Company's leadership and innovation in the pharmaceutical and chemical sectors. Mr. Xin emphasized that the award validates the Company's market position and reflects customer enthusiasm for their products, aiming to drive business growth and create long-term value for investors.
Qilian International Holding Group Limited (Nasdaq: QLI) reported a 9% revenue increase to $50 million for the fiscal year ended September 30, 2020, compared to $46.1 million in 2019. Key product segments such as oxytetracycline and heparin drove growth despite challenges from the COVID-19 pandemic. However, gross profit fell 22% to $7.5 million, with a gross margin decrease to 15.1%. Net income attributable to shareholders was $5.1 million, down 5% from the previous year. The company anticipates sustained demand growth in the long run and aims to leverage its recent IPO to pursue growth opportunities.
Qilian International Holding Group Limited (Nasdaq: QLI) announced the upcoming completion of the first phase expansion of its organic fertilizer production facility in Jiuquan City, Gansu Province, expected by March 2021. This expansion aims to triple its production capacity. The company has already secured government bids for organic fertilizer projects in Tibet, Gansu, and Qinghai. Chairman Zhanchang Xin highlighted the significant potential of the organic fertilizer market in China, positioning this segment as a future growth driver for the company.
Qilian International Holding Group Limited (Nasdaq: QLI) announced that underwriters fully exercised their option to purchase an additional 750,000 ordinary shares at $5.00 each during its IPO, totaling gross proceeds of $28.75 million. The shares began trading on January 12, 2021. Proceeds will fund investments in Oxytetracycline API production, an organic-waste treatment facility, Heparin Sodium Preparation facilities, and marketing for Gan Di Xin®. The IPO was managed by Univest Securities, LLC, with SEC registration declared effective on December 30, 2020.
Qilian International Holding Group Limited (Nasdaq: QLI) has completed its initial public offering, selling 5 million ordinary shares at $5.00 each, raising $25 million in gross proceeds. The offering includes a 45-day option for underwriters to purchase an additional 750,000 shares. Proceeds will fund investments in Oxytetracycline API production facilities, a waste treatment facility, and Heparin Sodium Preparation facilities, as well as marketing for Gan Di Xin®. The shares began trading on January 12, 2021.
ATIF Holdings Limited announced that its client, Qilian International Holding Group Limited, has officially launched its ordinary shares on the Nasdaq Global Market as of January 12, 2021. Qilian's initial public offering (IPO) priced 5,000,000 shares at $5.00 each, aiming for gross proceeds of $25 million. Additionally, underwriters have a 45-day option to purchase another 750,000 shares. Qilian operates in pharmaceutical and chemical production in China and has a broad market presence across various provinces.
Qilian International Holding Group Limited announced the pricing of its initial public offering (IPO) of 5,000,000 ordinary shares at $5.00 per share, aiming to raise $25 million. The shares will trade on Nasdaq under the ticker symbol QLI starting January 12, 2021. The company has also granted underwriters a 45-day option to buy an additional 750,000 shares. Proceeds will fund investments in Oxytetracycline production, an organic-waste treatment facility, and marketing for Gan Di Xin. The IPO is expected to close around January 14, 2021.